National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Certolizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 14/10/2019
Rapid review completed 14/11/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that certolizumab pegol not be considered for reimbursement at the submitted price*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.